公司概况 - 诺华公司是一家领先的全球医疗保健公司，以其创新药物闻名 [1] - 公司在制药行业是关键参与者，与辉瑞和默克等巨头竞争 [1] 2025年第三季度财务业绩 - 每股收益为2.25美元，略低于预期的2.26美元 [2] - 营收约为139亿美元，超过预期的138亿美元 [2] - 净利润显著增加至39.3亿美元，主要由关键药物销售增长驱动 [3] - 营收增长和净利润增加归因于关键药物的强劲销售，帮助抵消了专利到期带来的财务影响 [2][3] 估值与财务比率 - 市盈率约为26.16，反映了市场对其盈利的估值 [3] - 市销率约为4.59，企业价值与销售额比率约为5.07，凸显了公司强大的市场地位 [4] - 企业价值与营运现金流比率约为13.32，表明了其现金流效率 [4] - 盈利收益率约为3.82%，提供了投资回报的视角 [4] - 债务权益比约为0.78，显示了均衡的融资方式 [4] - 流动比率约为0.82，表明公司有能力用短期资产覆盖短期负债 [4]

Novartis (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 09:00 AM ET Speaker3Good morning and good afternoon, and welcome to the Novartis Q3 2025 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be in a listen-only mode, and the conference is being recorded. After the presentation, there'll be an opportunity to ask questions by pressing star one and one at any time during the conference. Please limit yourself to one question and return to th ...

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead and add valu ...

Content Click below to navigate through the document Company overview Financial review Conclusions Investor presentation October 28, 2025 Novartis Q3 Results | October 28, 2025 1 Content Click below to navigate through the document Appendix References Q3 2025 Results Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be i ...

You've really been spoiling the markets over the last 10 quarters. You've always beat expectations and then subsequently you were able to raise your guidance. You beat this time around even though it was a very narrow beat, but you didn't quite manage to raise your guidance.Talk to us about what you saw this quarter and why you're a little more cautious than in previous quarters maybe. >> Well, I think this is the first time in many quarters where we've had some generic expiries hit us. you know when you ac ...

（原标题：美股前瞻 | 三大股指期货齐涨，日对美投资大单或成美股牛市催化剂） 1. 10月28日(周二)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.27%，标普500指数期货涨0.03%，纳指期货涨0.12%。 2. 截至发稿，德国DAX指数涨0.16%，英国富时100指数跌0.07%，法国CAC40指数涨0.14%，欧洲斯托克50指数涨0.16%。 3. 截至发稿，WTI原油跌1.24%，报60.55美元/桶。布伦特原油跌1.17%，报64.14美元/桶。 市场消息 特朗普东京晚宴邀OpenAI、赛富时(CRM.US)CEO齐聚，共庆日对美投资大单。美国总统特朗普在结束对东京的访问前夕，计划与多位企业领袖 共进晚餐，届时将宣布日本对美投资成果。受邀嘉宾包括赛富时掌门马克·贝尼奥夫、东芝首席执行官岛田太郎、乐天集团创始人三木谷浩史等。 此次晚宴将在美国驻日大使乔治·格拉斯官邸举行，与会者还包括OpenAI联合创始人格雷格·布罗克曼、本田汽车(HMC.US)社长三部敏宏，以及安 杜里尔工业公司创始人帕尔默·勒基。此次晚宴适逢白宫宣布新一轮对美经济投资承诺。根据此前贸易框架，特朗普降低并设定了日本商品 ...

Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key me... ...

The CNBC app, global market news in one place. Customizable sections and personalized alerts, stocks tracking, interactive charts and market insights, all in your hands. Stay connected, stay informed.Download the CNBC app today. >> Welcome to Sportbox Europe. I'm Karen show with Juliana Tatlebomb.These are your headlines in corporate news. Nevada says it's well on track to achieve its guidance for the year as Q3 operating income surges by a quarter, countering the impact of generic drug erosion in the Unite ...

Swiss drugmaker Novartis is exploring options to add more medicines to its direct to patient platform that is expected to launch in the U.S. next month, CEO Vas Narasimhan told Reuters in an interview... ...

瑞士制药巨头诺华制药(NVS.US)盘前跌3%，报125.27美元。消息上，诺华第三季度销售净额139.1亿美 元，预估138.8亿美元；核心每股收益2.25美元，预估2.26美元；核心净利润43.3亿美元，预估44.2亿美 元。诺华重申了其2025年全年指引，维持高个位数的销售增长和低两位数的核心运营利润增长预期。 (格隆汇) | NVS 诺华制药 | | | | --- | --- | --- | | 129.140 ↓ -1.220 -0.94% | | 收盘价 10/27 15:59 美东 | | 125.270 -3.870 -3.00% | | 盘前价 10/28 04:19 美东 | | = 71 4 5 × × ■ ♥ 白选 | | ● 快捷交易 | | 最高价 130.170 | 开盘价 128.000 | 成交量 257.89万 | | 最低价 127.080 | 昨收价 130.360 | 成交额 3.32亿 | | 平均价 128.922 | 市空室 IM 18.83 | 总市值 2499.96亿(m) | | 振 幅 2.37% | 市盈率(静) 22.00 | 总股本 19.36亿 ...